{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:14:28Z","timestamp":1787933668953,"version":"build-2784847793"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"crossref","award":["R21520154121"],"award-info":[{"award-number":["R21520154121"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2995-7","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T12:57:19Z","timestamp":1541509039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Jeff Zarp","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejla Sjanic","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maj","family":"Vinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Balslev","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Ehrenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte Moos","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Vedel","family":"Kessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla Woznica","family":"Miskowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"issue":"3","key":"2995_CR1","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.4088\/JCP.14cs09399","volume":"76","author":"KE Burdick","year":"2015","unstructured":"Burdick KE, Ketter TA, Goldberg JF, Calabrese JR. Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J Clin Psychiatry. 2015;76(3):e342\u201350.","journal-title":"J Clin Psychiatry."},{"key":"2995_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jad.2016.08.018","volume":"205","author":"JH Jensen","year":"2016","unstructured":"Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. J Affect Disord. 2016;205:378\u201386.","journal-title":"J Affect Disord"},{"issue":"14","key":"2995_CR3","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1017\/S0033291714000439","volume":"44","author":"K Burdick","year":"2014","unstructured":"Burdick K, Russo M, Frangou S, Mahon K, Braga R, Shanahan M, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med. 2014;44(14):3083\u201396.","journal-title":"Psychol Med"},{"issue":"10","key":"2995_CR4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1017\/S0033291712002085","volume":"43","author":"E Bora","year":"2013","unstructured":"Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43(10):2017\u201326.","journal-title":"Psychol Med"},{"issue":"10","key":"2995_CR5","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1017\/S0033291713002535","volume":"44","author":"PL Rock","year":"2014","unstructured":"Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029\u201340.","journal-title":"Psychol Med"},{"issue":"6","key":"2995_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/da.22063","volume":"30","author":"RS McIntyre","year":"2013","unstructured":"McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515\u201327.","journal-title":"Depress Anxiety"},{"issue":"5","key":"2995_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1037\/a0029301","volume":"26","author":"BJ Hasselbalch","year":"2012","unstructured":"Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV. Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology. 2012;26(5):642\u201351.","journal-title":"Neuropsychology"},{"issue":"Suppl 2","key":"2995_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bdi.12341","volume":"17","author":"BT Baune","year":"2015","unstructured":"Baune BT, Malhi GS. A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder. Bipolar Disord. 2015;17(Suppl 2):41\u201355.","journal-title":"Bipolar Disord"},{"issue":"3","key":"2995_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/acps.12133","volume":"128","author":"C Bourne","year":"2013","unstructured":"Bourne C, Aydemir \u00d6, Balanz\u00e1-Mart\u00ednez V, Bora E, Brissos S, Cavanagh JTO, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128(3):149\u201362.","journal-title":"Acta Psychiatr Scand"},{"key":"2995_CR10","first-page":"3111","volume":"11","author":"B Bortolato","year":"2015","unstructured":"Bortolato B, Miskowiak KW, K\u00f6hler CA, Vieta E, Carvalho AF. Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses. Neuropsychiatr Dis Treat. 2015;11:3111\u201325.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"2995_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/bdi.12148","volume":"16","author":"S Tse","year":"2014","unstructured":"Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 2014;16(3):217\u201329.","journal-title":"Bipolar Disord"},{"issue":"1","key":"2995_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.psychres.2005.11.011","volume":"145","author":"J Jaeger","year":"2006","unstructured":"Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39\u201348.","journal-title":"Psychiatry Res"},{"issue":"1","key":"2995_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","volume":"19","author":"J Olesen","year":"2012","unstructured":"Olesen J, Gustavsson A, Svensson M, Wittchen HU, J\u00f6nsson B, on behalf of the Csg, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155\u201362.","journal-title":"Eur J Neurol"},{"issue":"5","key":"2995_CR14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00789056","volume":"30","author":"RJ Wyatt","year":"1995","unstructured":"Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness\u20131991. Soc Psychiatry Psychiatr Epidemiol. 1995;30(5):213\u20139.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"2995_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2008.06.009","volume":"113","author":"E Bora","year":"2009","unstructured":"Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: A meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord. 2009;113(1):1\u201320.","journal-title":"J Affect Disord"},{"key":"2995_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/bdi.12342","volume":"17","author":"RJ Porter","year":"2015","unstructured":"Porter RJ, Robinson LJ, Malhi GS, Gallagher P. The neurocognitive profile of mood disorders \u2013 a review of the evidence and methodological issues. Bipolar Disord. 2015;17:21\u201340.","journal-title":"Bipolar Disord"},{"issue":"8","key":"2995_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1017\/S0033291706007896","volume":"36","author":"MV Christensen","year":"2006","unstructured":"Christensen MV, Kyvik KO, Kessing LV. Cognitive function in unaffected twins discordant for affective disorder. Psychol Med. 2006;36(8):1119\u201329.","journal-title":"Psychol Med"},{"key":"2995_CR18","first-page":"62","volume":"3","author":"MS Keshavan","year":"2010","unstructured":"Keshavan MS, Kulkarni S, Bhojraj T, Francis A, Diwadkar V, Montrose DM, et al. Premorbid cognitive deficits in young relatives of schizophrenia patients. Front Hum Neurosci. 2010;3:62.","journal-title":"Front Hum Neurosci"},{"issue":"2\u20133","key":"2995_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.schres.2004.03.007","volume":"71","author":"MM Sitskoorn","year":"2004","unstructured":"Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res. 2004;71(2\u20133):285\u201395.","journal-title":"Schizophr Res"},{"issue":"8","key":"2995_CR20","doi-asserted-by":"publisher","first-page":"e747","DOI":"10.4088\/JCP.12m08258","volume":"74","author":"M Vinberg","year":"2013","unstructured":"Vinberg M, Miskowiak KW, Kessing LV. Impairment of executive function and attention predicts onset of affective disorder in healthy high-risk twins. J Clin Psychiatry. 2013;74(8):e747\u201353.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 3","key":"2995_CR21","doi-asserted-by":"publisher","first-page":"S499","DOI":"10.1016\/j.euroneuro.2012.08.002","volume":"22","author":"DV Iosifescu","year":"2012","unstructured":"Iosifescu DV. The relation between mood, cognition and psychosocial functioning in psychiatric disorders. Eur Neuropsychopharmacol. 2012;22(Suppl 3):S499\u2013504.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"2995_CR22","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.euroneuro.2016.08.011","volume":"26","author":"KW Miskowiak","year":"2016","unstructured":"Miskowiak KW, Carvalho AF, Vieta E, Kessing LV. Cognitive enhancement treatments for bipolar disorder: A systematic review and methodological recommendations. Eur Neuropsychopharmacol. 2016;26(10):1541\u201361.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2995_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.coph.2013.11.009","volume":"14","author":"PJ Nathan","year":"2014","unstructured":"Nathan PJ, Phan KL, Harmer CJ, Mehta MA, Bullmore ET. Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. Curr Opin Pharmacol. 2014;14:54\u201361.","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"2995_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrd3628","volume":"11","author":"MJ Millan","year":"2012","unstructured":"Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141\u201368.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2995_CR25","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1002\/hbm.22475","volume":"35","author":"B Dietsche","year":"2014","unstructured":"Dietsche B, Backes H, Stratmann M, Konrad C, Kircher T, Krug A. Altered neural function during episodic memory encoding and retrieval in major depression. Hum Brain Mapp. 2014;35(9):4293\u2013302.","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"2995_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eurpsy.2007.05.002","volume":"23","author":"S Frangou","year":"2008","unstructured":"Frangou S, Kington J, Raymont V, Shergill SS. Examining ventral and dorsal prefrontal function in bipolar disorder: a functional magnetic resonance imaging study. Eur Psychiatry. 2008;23(4):300\u20138.","journal-title":"Eur Psychiatry"},{"issue":"12","key":"2995_CR27","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1002\/hbm.20820","volume":"30","author":"LS Hamilton","year":"2009","unstructured":"Hamilton LS, Altshuler LL, Townsend J, Bookheimer SY, Phillips OR, Fischer J, et al. Alterations in functional activation in euthymic bipolar disorder and schizophrenia during a working memory task. Hum Brain Mapp. 2009;30(12):3958\u201369.","journal-title":"Hum Brain Mapp"},{"issue":"3","key":"2995_CR28","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.neuroimage.2005.02.048","volume":"26","author":"P-O Harvey","year":"2005","unstructured":"Harvey P-O, Fossati P, Pochon J-B, Levy R, LeBastard G, Leh\u00e9ricy S, et al. Cognitive control and brain resources in major depression: An fMRI study using the n-back task. NeuroImage. 2005;26(3):860\u20139.","journal-title":"NeuroImage"},{"issue":"8","key":"2995_CR29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/archgenpsychiatry.2009.91","volume":"66","author":"MJ Minzenberg","year":"2009","unstructured":"Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009;66(8):811\u201322.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"2995_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pscychresns.2009.11.010","volume":"182","author":"J Townsend","year":"2010","unstructured":"Townsend J, Bookheimer SY, Foland-Ross LC, Sugar CA, Altshuler LL. fMRI abnormalities in dorsolateral prefrontal cortex during a working memory task in manic, euthymic and depressed bipolar subjects. Psychiatry Res. 2010;182(1):22\u20139.","journal-title":"Psychiatry Res"},{"key":"2995_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.neubiorev.2015.08.015","volume":"57","author":"C Piguet","year":"2015","unstructured":"Piguet C, Fodoulian L, Aubry J-M, Vuilleumier P, Houenou J. Bipolar disorder: Functional neuroimaging markers in relatives. Neurosci Biobehav Rev. 2015;57:284\u201396.","journal-title":"Neurosci Biobehav Rev"},{"issue":"8","key":"2995_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1176\/appi.ajp.2009.08091307","volume":"166","author":"JD Ragland","year":"2009","unstructured":"Ragland JD, Laird AR, Ranganath C, Blumenfeld RS, Gonzales SM, Glahn DC. Prefrontal Activation Deficits During Episodic Memory in Schizophrenia. Am J Psychiatry. 2009;166(8):863\u201374.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2995_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.bpa.2010.10.005","volume":"24","author":"D Sargin","year":"2010","unstructured":"Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol. 2010;24(4):573\u201394.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"issue":"5","key":"2995_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1440-1819.2012.02359.x","volume":"66","author":"G Fond","year":"2012","unstructured":"Fond G, Macgregor A, Attal J, Larue A, Brittner M, Ducasse D, et al. Treating patients with schizophrenia deficit with erythropoietin? Psychiatry Clin Neurosci. 2012;66(5):375\u201382.","journal-title":"Psychiatry Clin Neurosci"},{"key":"2995_CR35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2119\/molmed.2012.00190","volume":"18","author":"A Kastner","year":"2012","unstructured":"Kastner A, Grube S, El-Kordi A, Stepniak B, Friedrichs H, Sargin D, et al. Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. Mol Med. 2012;18:1029\u201340.","journal-title":"Mol Med"},{"issue":"3","key":"2995_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00213-011-2511-1","volume":"219","author":"KW Miskowiak","year":"2012","unstructured":"Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology. 2012;219(3):687\u201398.","journal-title":"Psychopharmacology"},{"issue":"1","key":"2995_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","volume":"6","author":"AL Siren","year":"2009","unstructured":"Siren AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics. 2009;6(1):108\u201327.","journal-title":"Neurotherapeutics"},{"key":"2995_CR38","unstructured":"Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10\u20137."},{"issue":"12","key":"2995_CR39","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.4088\/JCP.13m08839","volume":"75","author":"KW Miskowiak","year":"2014","unstructured":"Miskowiak KW, Ehrenreich H, Christensen EM, Kessing LV, Vinberg M. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry. 2014;75(12):1347\u201355.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"2995_CR40","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/npp.2013.335","volume":"39","author":"KW Miskowiak","year":"2014","unstructured":"Miskowiak KW, Vinberg M, Christensen EM, Bukh JD, Harmer CJ, Ehrenreich H, et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology. 2014;39(6):1399\u2013408.","journal-title":"Neuropsychopharmacology"},{"issue":"Pt 10","key":"2995_CR41","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/brain\/awm203","volume":"130","author":"H Ehrenreich","year":"2007","unstructured":"Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130(Pt 10):2577\u201388.","journal-title":"Brain"},{"issue":"2","key":"2995_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/sj.mp.4001907","volume":"12","author":"H Ehrenreich","year":"2007","unstructured":"Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007;12(2):206\u201320.","journal-title":"Mol Psychiatry"},{"issue":"1\u20132","key":"2995_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2013.11.015","volume":"337","author":"W Jang","year":"2014","unstructured":"Jang W, Park J, Shin KJ, Kim JS, Kim JS, Youn J, et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson\u2019s disease. J Neurol Sci. 2014;337(1\u20132):47\u201354.","journal-title":"J Neurol Sci"},{"issue":"1","key":"2995_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1503\/jpn.140220","volume":"41","author":"J Macoveanu","year":"2016","unstructured":"Macoveanu J, Miskowiak K, Kessing LV, Vinberg M, Siebner HR. Healthy co-twins of patients with affective disorders show reduced risk-related activation of the insula during a monetary gambling task. J Psychiatry Neurosci. 2016;41(1):38\u201347.","journal-title":"J Psychiatry Neurosci"},{"issue":"8","key":"2995_CR45","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1017\/S0033291716000209","volume":"46","author":"KW Miskowiak","year":"2016","unstructured":"Miskowiak KW, Vinberg M, Glerup L, Paulson OB, Knudsen GM, Ehrenreich H, et al. Neural correlates of improved executive function following erythropoietin treatment in mood disorders. Psychol Med. 2016;46(8):1679\u201391.","journal-title":"Psychol Med"},{"issue":"11","key":"2995_CR46","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1523\/JNEUROSCI.5013-06.2007","volume":"27","author":"K Miskowiak","year":"2007","unstructured":"Miskowiak K, O'Sullivan U, Harmer CJ. Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci. 2007;27(11):2788\u201392.","journal-title":"J Neurosci"},{"issue":"1","key":"2995_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00213-009-1641-1","volume":"207","author":"KW Miskowiak","year":"2009","unstructured":"Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ, et al. Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology. 2009;207(1):133\u201342.","journal-title":"Psychopharmacology"},{"issue":"8","key":"2995_CR48","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.euroneuro.2016.05.009","volume":"26","author":"CV Ott","year":"2016","unstructured":"Ott CV, Vinberg M, Kessing LV, Miskowiak KW. The effect of erythropoietin on cognition in affective disorders\u2013Associations with baseline deficits and change in subjective cognitive complaints. Eur Neuropsychopharmacol. 2016;26(8):1264\u201373.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"2995_CR49","doi-asserted-by":"publisher","first-page":"e1639","DOI":"10.4088\/JCP.15m10480","volume":"77","author":"Kamilla Woznica Miskowiak","year":"2016","unstructured":"Miskowiak KW, Rush AJ, Gerds TA, Vinberg M, Kessing LV. Targeting treatments to improve cognitive function in mood disorder: suggestions from trials using erythropoietin. J Clin Psychiatry. 2016;77(12):e1639-46.","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"8","key":"2995_CR50","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bdi.12534","volume":"19","author":"KW Miskowiak","year":"2017","unstructured":"Miskowiak KW, Burdick KE, Martinez-Aran A, Bonnin CM, Bowie CR, Carvalho AF, McIntyre RS. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force.\u00a0Bipolar Disord.\u00a02017;19(8):614-26.","journal-title":"Bipolar Disorders"},{"key":"2995_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2995_CR52","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u201335.","journal-title":"Br J Psychiatry"},{"key":"2995_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jad.2015.07.039","volume":"187","author":"JH Jensen","year":"2015","unstructured":"Jensen JH, Stottrup MM, Nayberg E, Knorr U, Ullum H, Purdon SE, et al. Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools. J Affect Disord. 2015;187:10\u20139.","journal-title":"J Affect Disord"},{"key":"2995_CR54","volume-title":"The Screen for Cognitive Impairment in Psychiatry: Administration and Psychometric Properties","author":"SE Purdon","year":"2005","unstructured":"Purdon SE. The Screen for Cognitive Impairment in Psychiatry: Administration and Psychometric Properties. Edmonton: PNL, Inc.; 2005."},{"key":"2995_CR55","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jad.2015.10.059","volume":"190","author":"CV Ott","year":"2016","unstructured":"Ott CV, Bjertrup AJ, Jensen JH, Ullum H, Sjaelland R, Purdon SE, et al. Screening for cognitive dysfunction in unipolar depression: Validation and evaluation of objective and subjective tools. J Affect Disord. 2016;190:607\u201315.","journal-title":"J Affect Disord"},{"issue":"4","key":"2995_CR56","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.2044-8260.1987.tb01366.x","volume":"26","author":"JR Crawford","year":"1987","unstructured":"Crawford JR, Besson JAO, Parker DM, Sutherland KM, Keen PL. Estimation of premorbid intellectual status in depression. Br J Clin Psychol. 1987;26(4):313\u20134.","journal-title":"Br J Clin Psychol"},{"issue":"6","key":"2995_CR57","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archpsyc.1990.01810180089012","volume":"47","author":"JK Wing","year":"1990","unstructured":"Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990;47(6):589\u201393.","journal-title":"Arch Gen Psychiatry"},{"key":"2995_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1745-6215-11-97","volume":"11","author":"KW Miskowiak","year":"2010","unstructured":"Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Knudsen GM, Macoveanu J, et al. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials. 2010;11:97.","journal-title":"Trials"},{"issue":"1","key":"2995_CR59","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.mp.4001442","volume":"9","author":"H Ehrenreich","year":"2004","unstructured":"Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry. 2004;9(1):42\u201354.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"2995_CR60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193\u2013213.","journal-title":"Psychiatry Res"},{"issue":"3","key":"2995_CR61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00221-007-1102-1","volume":"184","author":"K Miskowiak","year":"2008","unstructured":"Miskowiak K, Inkster B, O'Sullivan U, Selvaraj S, Goodwin GM, Harmer CJ. Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res. 2008;184(3):313\u201321.","journal-title":"Exp Brain Res"},{"key":"2995_CR62","volume-title":"Rey auditory verbal learning test: A handbook (p. 1996)","author":"M Schmidt","year":"1996","unstructured":"Schmidt M. Rey auditory verbal learning test: A handbook (p. 1996). Los Angeles: Western Psychological Services; 1996."},{"issue":"3","key":"2995_CR63","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310\u20139.","journal-title":"J Clin Exp Neuropsychol"},{"key":"2995_CR64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0028-3932(67)90015-2","volume":"5","author":"J Borkowski","year":"1967","unstructured":"Borkowski J, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135\u201340.","journal-title":"Neuropsychologia"},{"key":"2995_CR65","doi-asserted-by":"crossref","unstructured":"Wechsler D. Wechsler Adult Intelligence Scale, 3rd ed. (WAIS-III). San Antonio: The Psychological Corporation; 1997.","DOI":"10.1037\/t49755-000"},{"key":"2995_CR66","unstructured":"Army Individual Test Battery. Manual of directions and scoring. Washington, DC: War Department, Adjutant General\u2019s Office; 1944."},{"key":"2995_CR67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1745-0179-3-5","volume":"3","author":"AR Rosa","year":"2007","unstructured":"Rosa AR, Sanchez-Moreno J, Martinez-Aran A, Salamero M, Torrent C, Reinares M, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.","journal-title":"Clin Pract Epidemiol Ment Health"},{"issue":"3","key":"2995_CR68","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1023\/A:1008815005736","volume":"8","author":"G Hawthorne","year":"1999","unstructured":"Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of Health-Related Quality of Life. Qual Life Res. 1999;8(3):209\u201324.","journal-title":"Qual Life Res"},{"issue":"1","key":"2995_CR69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jad.2013.02.022","volume":"150","author":"AR Rosa","year":"2013","unstructured":"Rosa AR, Mercad\u00e9 C, S\u00e1nchez-Moreno J, Sol\u00e9 B, Mar Bonnin CD, Torrent C, et al. Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). J Affect Disord. 2013;150(1):29\u201336.","journal-title":"J Affect Disord"},{"key":"2995_CR70","volume-title":"The Anxiety Disease","author":"DV Sheehan","year":"1983","unstructured":"Sheehan DV. The Anxiety Disease. New York: Charles Scribner\u2019s Sons; 1983."},{"issue":"2","key":"2995_CR71","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/oxfordjournals.schbul.a006870","volume":"27","author":"TL Patterson","year":"2001","unstructured":"Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27(2):235\u201345.","journal-title":"Schizophr Bull"},{"key":"2995_CR72","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1745-6215-12-35","volume":"12","author":"L Vesterager","year":"2011","unstructured":"Vesterager L, Christensen TO, Olsen BB, Krarup G, Forchhammer HB, Melau M, et al. Cognitive training plus a comprehensive psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for patients with first-episode schizophrenia (the NEUROCOM trial): a study protocol for a centrally randomised, observer-blinded multi-centre clinical trial. Trials. 2011;12:35.","journal-title":"Trials"},{"key":"2995_CR73","unstructured":"The WHOQOL Group. The Development of the World Health Organization Quality of Life Assessment Instrument (the WHOQOL). In: Orley J, Kuyken W, editors. Berlin: Quality of Life Assessment: International Perspectives. Springer; 1994."},{"issue":"5","key":"2995_CR74","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1192\/bjp.180.5.461","volume":"180","author":"JC Mundt","year":"2002","unstructured":"Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180(5):461\u20134.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"2995_CR75","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0145-2134(94)00131-6","volume":"19","author":"B Sanders","year":"1995","unstructured":"Sanders B, Becker-Lausen E. The measurement of psychological maltreatment: Early data on the child abuse and trauma scale. Child Abuse Negl. 1995;19(3):315\u201323.","journal-title":"Child Abuse Negl"},{"issue":"1","key":"2995_CR76","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbi.2011.07.239","volume":"26","author":"HH Chang","year":"2012","unstructured":"Chang HH, Lee IH, Gean PW, Lee S-Y, Chi MH, Yang YK, et al. Treatment response and cognitive impairment in major depression: Association with C-reactive protein. Brain Behav Immun. 2012;26(1):90\u20135.","journal-title":"Brain Behav Immun"},{"issue":"2","key":"2995_CR77","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jad.2013.04.039","volume":"150","author":"F Dickerson","year":"2013","unstructured":"Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150(2):456\u20139.","journal-title":"J Affect Disord"},{"issue":"4","key":"2995_CR78","first-page":"540","volume":"32","author":"R Grassi-Oliveira","year":"2011","unstructured":"Grassi-Oliveira R, Bauer ME, Pezzi JC, Teixeira AL, Brietzke E. Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol Lett. 2011;32(4):540\u20134.","journal-title":"Neuro Endocrinol Lett"},{"key":"2995_CR79","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jad.2015.08.058","volume":"188","author":"JD Rosenblat","year":"2015","unstructured":"Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, McIntyre RS. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. J Affect Disord. 2015;188:149\u201359.","journal-title":"J Affect Disord"},{"issue":"3","key":"2995_CR80","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.psychres.2015.05.078","volume":"228","author":"V Uyanik","year":"2015","unstructured":"Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik Mehmet S. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res. 2015;228(3):386\u201392.","journal-title":"Psychiatry Res"},{"issue":"5","key":"2995_CR81","doi-asserted-by":"publisher","first-page":"e0127629","DOI":"10.1371\/journal.pone.0127629","volume":"10","author":"M Vinberg","year":"2015","unstructured":"Vinberg M, Miskowiak K, Hoejman P, Pedersen M, Kessing LV. The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study. PLoS One. 2015;10(5):e0127629.","journal-title":"PLoS One"},{"key":"2995_CR82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbi.2016.05.006","volume":"57","author":"Maj Vinberg","year":"2016","unstructured":"Vinberg M, Weikop P, Olsen NV, Kessing LV, Miskowiak K. Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study. Brain Behav Immun. 2016;57:53\u20137.","journal-title":"Brain, Behavior, and Immunity"},{"key":"2995_CR83","doi-asserted-by":"publisher","unstructured":"Vinberg M, Hojman P, Pedersen BK, Kessing LV, Miskowiak KW. Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders. Acta Neuropsychiatr. 2018;1\u20138. https:\/\/doi.org\/10.1017\/neu.2018.16 .","DOI":"10.1017\/neu.2018.16"},{"key":"2995_CR84","doi-asserted-by":"publisher","unstructured":"Seeberg I, Kjaerstad HL, Miskowiak KW. Neural and behavioral predictors of treatment efficacy on mood symptoms and cognition in mood disorders: a systematic review.\u00a0Front Psychiatry. 2018;9:337. https:\/\/doi.org\/10.3389\/fpsyt.2018.00337 .","DOI":"10.3389\/fpsyt.2018.00337"},{"issue":"6","key":"2995_CR85","doi-asserted-by":"publisher","first-page":"e015462","DOI":"10.1136\/bmjopen-2016-015462","volume":"7","author":"LV Kessing","year":"2017","unstructured":"Kessing LV, Munkholm K, Faurholt-Jepsen M, Miskowiak KW, Nielsen LB, Frikke-Schmidt R, et al. The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open. 2017;7(6):e015462.","journal-title":"BMJ Open"},{"issue":"5","key":"2995_CR86","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jpsychires.2013.01.013","volume":"47","author":"M Vinberg","year":"2013","unstructured":"Vinberg M, Miskowiak K, Kessing LV. Risk markers for affective disorder, a seven-years follow up study of a twin cohort at low and high risk for affective disorder. J Psychiatr Res. 2013;47(5):565\u201371.","journal-title":"J Psychiatr Res"},{"issue":"7","key":"2995_CR87","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4088\/JCP.v69n0712","volume":"69","author":"CT Gualtieri","year":"2008","unstructured":"Gualtieri CT, Morgan DW. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J Clin Psychiatry. 2008;69(7):1122\u201330.","journal-title":"J Clin Psychiatry."},{"key":"2995_CR88","unstructured":"FDA\u00a0Critical Path Initiative.\u00a0 http:\/\/www.fda.gov\/oc\/initiatives\/criticalpath \/ http:\/\/www.nimh.nih.gov\/about\/director\/2014\/a-new-approach-to-clinical-trials.shtml ."},{"issue":"1","key":"2995_CR89","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1037\/prj0000189","volume":"40","author":"CR Bowie","year":"2017","unstructured":"Bowie CR, Grossman M, Gupta M, Holshausen K, Best MW. Action-based cognitive remediation for individuals with serious mental illnesses: Effects of real-world simulations and goal setting on functional and vocational outcomes. Psychiatr Rehabil J. 2017;40(1):53.","journal-title":"Psychiatr Rehabil J."},{"issue":"6","key":"2995_CR90","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1600-0447.2009.01503.x","volume":"120","author":"E Vieta","year":"2009","unstructured":"Vieta E. The influence of medications on neurocognition in bipolar disorder. Acta Psychiatr Scand. 2009;120(6):414\u20135.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"2995_CR91","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ctrv.2004.04.005","volume":"30","author":"E Ferrario","year":"2004","unstructured":"Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev. 2004;30(6):563\u201375.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"2995_CR92","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1161\/STROKEAHA.109.564872","volume":"40","author":"H Ehrenreich","year":"2009","unstructured":"Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12):e647\u201356.","journal-title":"Stroke"},{"issue":"12","key":"2995_CR93","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/eci.12357","volume":"44","author":"A Lund","year":"2014","unstructured":"Lund A, Lundby C, Olsen NV. High-dose erythropoietin for tissue protection. Eur J Clin Investig. 2014;44(12):1230\u20138.","journal-title":"Eur J Clin Investig"},{"key":"2995_CR94","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fimmu.2014.00563","volume":"5","author":"N Debeljak","year":"2014","unstructured":"Debeljak N, Solar P, Sytkowski AJ. Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol. 2014;5:563.","journal-title":"Front Immunol"},{"issue":"8","key":"2995_CR95","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/j.1537-2995.2008.01749.x","volume":"48","author":"JM McKoy","year":"2008","unstructured":"McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48(8):1754\u201362.","journal-title":"Transfusion"},{"issue":"21","key":"2995_CR96","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019\u201332.","journal-title":"N Engl J Med"},{"issue":"9559","key":"2995_CR97","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","volume":"369","author":"A Phrommintikul","year":"2007","unstructured":"Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381\u20138.","journal-title":"Lancet"},{"issue":"12","key":"2995_CR98","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.euroneuro.2016.09.641","volume":"26","author":"KW Miskowiak","year":"2016","unstructured":"Miskowiak KW, Ott CV, Petersen JZ, Kessing LV. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. Eur Neuropsychopharmacol. 2016;26(12):1845\u201367.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2995_CR99","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1192\/bjp.bp.106.028555","volume":"190","author":"MA Posternak","year":"2007","unstructured":"Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry. 2007;190:287\u201392.","journal-title":"Br J Psychiatry"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2995-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2995-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2995-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T11:26:41Z","timestamp":1662377201000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2995-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2995"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2995-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"2 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has been approved by the Danish Medicines Agency (EudraCT number 2016\u2013004023-24), the Ethics Committee in the Capital Region of Denmark (protocol number H-16043370), and The Danish Data Protection Agency Capital Region of Denmark (protocol number RHP-2017-020) and has been retrospectively registered at(NCT03315897)on 20th October 2017. Any important protocol modifications will be reported to the Danish Medicines Agency, the Ethics Committee in the Capital Region of Denmark, and the Danish Data Protection Agency. Written informed consent has been and will be obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JZP, LSS, MBJ, and IH declare no competing interests. KWM has received consultancy fees from Lundbeck and Allergan. MV discloses consultancy fees from Lundbeck and Astra Zeneca within the last three\u00a0years. GMK was supported by a Center grant from the Innovation Fond, Center for Experimental Medicine Neuropharmacology (Neuropharm). LVK reports having been a consultant for Lundbeck, AstraZeneca, and Sunovion within the last three\u00a0years. HE holds user patents for EPO in stroke, schizophrenia, and MS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"611"}}